For many, the COVID-19 outbreak is the greatest challenge of our careers.
We’re doing everything we can to help.
Since the pandemic began, traffic to our website has doubled, and our one-to-one support team has helped more than a thousand pharmacists.
Our members make all this possible. Without this income, we can’t keep supporting pharmacists.
So we need your support. If you find our tools and guidance useful, we need you to become a member — and to help us do even more.
Joining costs just 60p a day, and means, whatever the future of pharmacy looks like, we’ll be there to put it at the forefront of healthcare.
Advice on ibuprofen will be updated in Europe following final approval by the Co-ordination Group for Mutual Recognition and Decentralised Procedures – Human (part of the European Medicines Agency). Updated advice was recommended by the Pharmacovigilance Risk Assessment Committee (PRAC) following a review by PRAC that confirmed an increased risk of cardiovascular problems at doses at or above 2,400mg of ibuprofen a day. Higher doses of ibuprofen should be avoided in patients with underlying ...
Are you already a member of the Royal Pharmaceutical Society or a registered user?Sign in here
Subscribe for as little as £5, to gain full, unlimited access to the ultimate source of information and news on pharmacy and pharmaceutical sciences.Subscribe today
Alternatively, register for free to the site for access to an extra 2 premium articles for free.Register now.
Please contact The Pharmaceutical Journal directly, so we can provide you with detailed information about our institutional and corporate offerings.
Tel: 0044 20 3318 3141
As a pharmacist or pharmaceutical scientist, join the Royal Pharmaceutical Society and gain full access to pharmaceutical-journal.com
Membership is free for pharmacy students.
If you are not registered as a pharmacist in Great Britain or practise overseas, you may still be able to join the RPS as an associate member.Become a member